Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics


Y-mAbs Therapeutics, Inc. (YMAB)

Today's Latest Price: $43.06 USD

0.06 (-0.14%)

Updated Jan 27 4:00pm

Add YMAB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

YMAB Stock Price Chart Interactive Chart >

Price chart for YMAB

YMAB Price/Volume Stats

Current price $43.06 52-week high $55.22
Prev. close $43.12 52-week low $14.16
Day low $41.15 Volume 310,359
Day high $45.14 Avg. volume 233,621
50-day MA $49.12 Dividend yield N/A
200-day MA $42.45 Market Cap 1.74B

Y-mAbs Therapeutics, Inc. (YMAB) Company Bio


Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.


YMAB Latest News Stream


Event/Time News Detail
Loading, please wait...

YMAB Latest Social Stream


Loading social stream, please wait...

View Full YMAB Social Stream

Latest YMAB News From Around the Web

Below are the latest news stories about Y-mAbs Therapeutics Inc that investors may wish to consider to help them evaluate YMAB as an investment opportunity.

Y-mAbs Therapeutics (YMAB) Investor Presentation - Slideshow

The following slide deck was published by Y-mAbs Therapeutics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 21, 2021

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Claus Møller, MD, Ph.D., Chief Executive Officer of Y-mAbs Therapeutics will provide an overview and update on the company's business at the virtual 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 12, 2021, at 10:00 AM Eastern Standard Time. The presentation can be accessed via a live webcast. About Y-mAbsY-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based t...

Yahoo | January 6, 2021

H.C. Wainwright Stick to Their Buy Rating for Y-Mabs Therapeutics Inc

H.C. Wainwright Stick to Their Buy Rating for Y-Mabs Therapeutics Inc

Investing.com | December 28, 2020

Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a license agreement with SciClone Pharmaceuticals International Ltd (“SciClone”) to be the exclusive co-development and commercialization partner of the Company’s antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in China. DANYELZA (naxitamab-gqgk) 40mg/10mL was approved by the U.S. ...

Yahoo | December 18, 2020

Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that it has entered into a distribution agreement with Swixx BioPharma AG (“Swixx”) to be the exclusive distributor of the Company’s antibodies, DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russia. DANYELZA (naxitamab-gqgk) 40mg/10mL was approved by the U.S. Food and Drug Administration...

Yahoo | December 18, 2020

Read More 'YMAB' Stories Here

YMAB Price Returns

1-mo -15.04%
3-mo -0.69%
6-mo 22.57%
1-year 20.28%
3-year N/A
5-year N/A
YTD -13.03%
2020 58.43%
2019 53.64%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8024 seconds.